Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 6/20 | 0.76 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | DHODH | Q02127 | 5/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL291134 | 0.95 | PDE5A (0.70) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL29831813 | 0.95 | PDE5A (0.70) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL290739 | 0.95 | PDE5A (0.70) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL29831798 | 0.95 | PDE5A (0.70) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL291449 | 0.91 | PDE5A (0.64) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL6068322 | 0.90 | PDE5A (0.71) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL290735 | 0.88 | PDE5A (0.78) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL291575 | 0.88 | PDE5A (0.60) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL298868 | 0.87 | PDE5A (0.59) | PDE5AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL290844 | 0.87 | PDE5A (1.00) | PDE5AMAPTKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024038089-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-22 | — | — | WO | disclosed |
| EP-2846805-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | Omeros Corporation (US) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013176877-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | OMEROS CORPORATION (US) | 2013-11-28 | — | — | WO | disclosed |
| EP-2640395-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | Omeros Corporation (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012064667-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | OMEROS CORPORATION (US) | 2012-05-18 | — | — | WO | disclosed |
| EP-2427193-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | Omeros Corporation (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129036-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION (US) | 2010-11-11 | — | — | WO | disclosed |